MedTrace Logo

Pharmacokinetic Study of Therapeutic Plasma Exchange

NCT07756242 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2026-08-10

No results posted yet for this study

Summary

The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.

Conditions

  • Immune-related Adverse Event

Interventions

DEVICE

Spectra Optia Apheresis System

Therapeutic plasma exchange (using the Spectra Optia Apheresis System) will be done according to standard of care.

Sponsors & Collaborators

Principal Investigators

  • Pankti Reid · University of Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-30
Primary Completion
2027-11-30
Completion
2028-02-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07756242 on ClinicalTrials.gov